Ken Griffin Rx Sight, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$40.78 - $57.04 $212,056 - $296,608	5,200 Added 108.33%	10,000 $494,000
Q2 2024 Aug 14, 2024	BUY	$50.42 - $64.29 $141,176 - $180,012	2,800 Added 140.0%	4,800 $288,000
Q1 2024 May 15, 2024	SELL	$35.51 - $57.92 $28,408 - $46,336	-800 Reduced 28.57%	2,000 $103,000
Q4 2023 Feb 14, 2024	BUY	$20.91 - $40.9 $14,637 - $28,630	700 Added 33.33%	2,800 $112,000
Q3 2023 Nov 14, 2023	SELL	$27.05 - $33.37 $35,165 - $43,381	-1,300 Reduced 38.24%	2,100 $58,000
Q2 2023 Aug 14, 2023	SELL	$16.37 - $28.9 $58,932 - $104,040	-3,600 Reduced 51.43%	3,400 $97,000
Q1 2023 May 15, 2023	BUY	$12.58 - $16.68 $75,480 - $100,080	6,000 Added 600.0%	7,000 $116,000
Q4 2022 Feb 14, 2023	BUY	$9.93 - $14.2 $9,930 - $14,200	1,000 New	1,000 $12,000

224

32.3M

394K

32K

Ticker RXST
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 27,638,900
Market Cap $930M
Description
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. T...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.